Any violation of ceiling prices of drugs is dealt sternly: NPPA

Excelsior Correspondent
JAMMU, Sept 29: National Pharmaceutical Pricing Authority (NPPA) today said that it takes stern action in any violation of ceiling prices fixed by it for scheduled formulations, retail prices fixed by it for new drugs and increasing MRP of non-scheduled drugs by more than 10 percent.
“We strongly condemned false statements regarding our connivance in any of the malpractices adopted by the pharmaceutical companies,” NPPA said in a handout issued today. It added that charging different prices below the applicable ceiling price/MRP to different sectors by pharmaceutical companies is not under its purview and it is done purely on commercial terms by the companies.
The handout reads that NPPA is a regulatory body under Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India and is committed to ensure affordability and accessibility of medicines by fixing and monitoring the prices of non-scheduled formulations.